Inotiv, Inc.

Equities

NOTV

US45783Q1004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
1.87 ^USD	-4.10%		-6.50%	-49.05%

17/05	North American Morning Briefing : The "Everything -2-	DJ
16/05	Craig Hallum Adjusts Inotiv Price Target to $10 From $25, Maintains Buy Rating	MT

Inotiv, Inc. Withdraws Financial Guidance for Fiscal Year 2024

May 16, 2024 at 01:35 am IST

Inotiv, Inc. announced that due to the significant impact that NHP revenue has on consolidated revenue and margins, and the current uncertainty in customer demand for NHPs, the company is withdrawing financial guidance for fiscal year 2024.

Latest news about Inotiv, Inc.

North American Morning Briefing : The "Everything -2-	17/05	DJ
Craig Hallum Adjusts Inotiv Price Target to $10 From $25, Maintains Buy Rating	16/05	MT
Inotiv, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	16/05	CI
Earnings Flash (NOTV) INOTIV Posts Q2 Revenue $119M, vs. Street Est of $133.1M	16/05	MT
Inotiv, Inc. Withdraws Financial Guidance for Fiscal Year 2024	16/05	CI
Wall Street Set to Open Flat Tuesday as Key Inflation Gauge Rises More Than Expected	14/05	MT
Top Premarket Decliners	14/05	MT
Investors Await Key Inflation Data as US Futures Tread Water in Premarket Session	14/05	MT
Jefferies Downgrades Inotiv to Hold From Buy, Price Target is $3.75	14/05	MT
Inotiv Delays Release of Fiscal Q2 Results	10/05	MT
Inotiv, Inc. Elects Michael J. Harrington as Class III Member of the Board	20/03	CI
North American Morning Briefing : Stock Futures -2-	12/02	DJ
Jefferies Upgrades Inotiv to Buy Rating From Hold, Adjusts Price Target to $11.50 From $3	09/02	MT
Inotiv, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	08/02	CI
Transcript : Inotiv, Inc., Q1 2024 Earnings Call, Feb 07, 2024	08/02
Earnings Flash (NOTV) INOTIV Reports Q1 Revenue $135.5M, vs. Street Est of $132.9M	08/02	MT
Inotiv, Inc. Reaffirms Earnings Guidance for the Fiscal 2024	08/02	CI
An unknown buyer acquired RMS facilities in Spain and France from Inotiv, Inc..	07/02	CI
Jefferies Adjusts Inotiv Price Target to $3 From $7.25, Maintains Hold Rating	13/12	MT
Craig-Hallum Adjusts Price Target on Inotiv to $25 From $34, Maintains Buy Rating	12/12	MT
Inotiv Q4 Loss Narrows, Revenue Falls; Issues Fiscal 2024 Guidance -- Shares Rise After Hours	12/12	MT
Inotiv, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12/12	CI
Earnings Flash (NOTV) INOTIV Reports Q4 Revenue $140.7M, vs. Street Est of $139.4M	12/12	MT
Inotiv, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	12/12	CI
Inotiv, Inc. Provides Earnings Guidance for the Fiscal Year 2024	12/12	CI

Chart Inotiv, Inc.

Duration

Period

More charts

Company Profile

Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - Jefferies Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Inotiv, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.87 USD

Average target price

4.667 USD

Spread / Average Target

+149.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INOTIV, INC.	-49.05%	4.86Cr
MODERNA, INC.	+43.36%	5.46TCr
IQVIA HOLDINGS INC.	-5.31%	3.99TCr
LONZA GROUP AG	+37.52%	3.88TCr
ICON PUBLIC LIMITED COMPANY	+14.75%	2.69TCr
CELLTRION, INC.	-12.56%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	1.88TCr
UNITED THERAPEUTICS CORPORATION	+25.12%	1.22TCr
BIO-TECHNE CORPORATION	+0.04%	1.22TCr
MEDPACE HOLDINGS, INC.	+26.04%	1.19TCr

Other Biotechnology & Medical Research